March 6, 2020 / 7:09 AM / a month ago

BRIEF-Astrazeneca Says Phase III Danube Trial In Unresectable, Stage IV Bladder Cancer Did Not Meet Primary Endpoints

March 6 (Reuters) - AstraZeneca PLC:

* ASTRAZENECA PLC - UPDATE ON PHASE III DANUBE TRIAL IN BLADDER CANCER

* PHASE III DANUBE TRIAL FOR IMFINZI AND IMFINZI PLUS TREMELIMUMAB IN UNRESECTABLE, STAGE IV BLADDER CANCER DID NOT MEET PRIMARY ENDPOINTS

* SAFETY AND TOLERABILITY PROFILES FOR IMFINZI AND COMBINATION WITH TREMELIMUMAB WERE CONSISTENT WITH PREVIOUS TRIALS

* SAFETY AND TOLERABILITY PROFILES FOR IMFINZI AND COMBINATION WITH TREMELIMUMAB WERE CONSISTENT WITH PREVIOUS TRIALS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below